Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Mar 27, 2014 (13 years ago)

Spiriva HandiHaler (Tiotropium Bromide)

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Defective Delivery System: Potential for dose delivery out of specification due to interation of the drug product powder with the lubricant on the interior of the capsule shell.

Cause type: Packaging defect

Failed child-resistant closures, leaks, cracked containers, or a defective delivery device. Packaging failures risk accidental exposure (especially to children) or product contamination. All packaging defect recalls.

What was recalled

Spiriva HandiHaler (tiotropium bromide inhalation powder), Do Not Swallow Spiriva Capsules, For Use With HandiHaler Only, 18 mcg (as tiotropium) per capsule, Rx Only, a) NDC 0597-0075-75, 5 Spiriva capsules per blister card, b) NDC 0597-0075-41, 30 Spiriva capsules per blister card, Manufactured by: Boehringer Ingelheim (BI) Pharma, GmbH & Co. KG, Ingelheim, Germany, Marketed by: Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT 06877 USA and Pfizer Inc New York, NY 10017 USA, Made in Germany.

Affected NDCs 0597-0075-41 0597-0075-75

Compare with the code on your package — it is the most precise check available.

Drug: Tiotropium

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Spiriva HandiHaler
Tiotropium Bromide
NDC 00597-0075
MONOHYDRATE 18 ug/1 Capsule
Oral|respiratory (inhalation)
Boehringer Ingelheim Pharmaceuticals, Inc. Rx
Recalling firm
Boehringer Ingelheim Roxane Inc
NDC code
0597-0075-75
Origin
OH, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1230-2014 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Tiotropium recalls

See all
Class II · Moderate risk

Spiriva Handihaler

CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.

Terminated Temperature excursion Cardinal Healthcare D-0197-2024
Class II · Moderate risk

Spiriva HandiHaler

CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Terminated Temperature excursion Cardinal Health Inc. NDC 0597-0075-41 D-0453-2021
Class III · Low risk

SPIRIVA HandiHaler

Presence of Foreign Substance: This recall is being conducted due to the potential for extrinsic foreign particles in the API used to manufacture SPIRIVA Handihaler

Terminated Particulate / foreign matter Boehringer Ingelheim Roxane Inc NDC 0597-0075-27 D-1057-2013

Other recalls by Boehringer Ingelheim Roxane Inc

All 2014 recalls
Class III · Low risk

FUROSEMIDE Tablets USP

CGMP Deviations: The active pharmaceutical ingredient (API) intended for use in furosemide oral solution USP was inadvertently used to manufacture the recalled furosemide tablets USP.

Terminated cGMP deviation Boehringer Ingelheim Roxane Inc NDC 0054-4299-31 D-0012-2016
Class III · Low risk

FUROSEMIDE Tablets USP

CGMP Deviations: The active pharmaceutical ingredient (API) intended for use in furosemide oral solution USP was inadvertently used to manufacture the recalled furosemide tablets USP.

Terminated cGMP deviation Boehringer Ingelheim Roxane Inc NDC 0054-4297-31 D-0011-2016
Class II · Moderate risk

Combivent Respimat

Defective Delivery System: Inhalers do not spray properly, emitting either no spray or a short transient spray.

Terminated Packaging defect Boehringer Ingelheim Roxane Inc NDC 0597-0024-02 D-1279-2015